thats a set back on one of our verticals, but is why diversification is good, and we have multiple MTAs and verticals.
Richard Jagger, CEO & MD of Bio-Gene said, “We are disappointed with the decision made by BASF today, however we respect its needs to follow its own commercial strategy. We still have a lot of faith in the positive data generated and will continue to work with GRDC and DAF to advance this project. Bio-Gene has always had a strategy of working with a number of potential commercial partners under our multiple material transfer agreement approach, and we now will shift our focus to other companies who have shown interest in this opportunity. Pleasingly, our programs with Evergreen and Clarke are continuing to advance well.”
